News for STIM Stock

Neuronetics Announces Clinical Presence at the 2025 Clinical TMS Society Annual Meeting and Progress in Greenbrook’s Personalized Care Trial Program Neuronetics Set to Join Russell 2000® and Russell 3000® Indexes Neuronetics Launches First Inaugural National TMS Therapy Awareness Day During Mental Health Awareness Month Neuronetics Reports First Quarter 2025 Financial and Operating Results Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Neuronetics to Report First Quarter 2025 Financial and Operating Results and Host Conference Call Evernorth Health Services, a Cigna Company, Expands NeuroStar® TMS Coverage for Adolescents Struggling with Depression Neuronetics Reports Updated Fourth Quarter and Full Year 2024 Financial and Operating Results Neuronetics Reports Fourth Quarter and Full Year 2024 Financial and Operating Results Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Neuronetics to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Neuronetics Announces Pricing of $18 Million Underwritten Public Offering of Common Stock Neuronetics Announces Launch of Underwritten Public Offering of Common Stock NeuroStar Unveils Two Significant Publications on TMS Therapy for Depression Neuronetics Provides Business Update and Issues 2025 Guidance Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Neuronetics and Greenbrook TMS Announce Closing of Transaction Neuronetics to Present at the Piper Sandler 36th Annual Healthcare Conference CORRECTION—Neuronetics Reports Record Third Quarter 2024 Financial and Operating Results Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Neuronetics Reports Record Third Quarter 2024 Financial and Operating Results Neuronetics to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call NeuroStar® Oral Presentation at AACAP 2024 Highlights Largest Study Evaluating TMS Efficacy in Adolescents with Depression Neuronetics and Greenbrook TMS Announce Receipt of Interim Order in Respect of Proposed Arrangement and Provide Details of Shareholder Meetings Health Care Service Corporation Adds First-Line TMS Coverage for Adolescents Expanded Health Policies Enhance TMS Therapy Access for Adolescents and Adults NeuroStar® Releases Software Upgrades to Elevate Patient Care NeuroStar Honors Suicide Prevention Month With Milestone Achievement and Powerful Stories NeuroStar® Marks Two Years of Transformative Impact with NeuroStar University Neuronetics and Greenbrook TMS Announce Definitive Agreement to Merge Neuronetics Reports Record Second Quarter 2024 Financial and Operating Results Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) NeuroStar Partners With This Is My Brave to Recognize Teen Mental Health Month Neuronetics to Present at the Canaccord Genuity 44th Annual Growth Conference Neuronetics Announces the Closing of up to $90 Million Senior Secured Credit Facility with Perceptive Advisors Neuronetics to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call Aetna Policy Update Expands TMS Availability for Adolescents With Depression California Medicaid Adds TMS Access for 14.8 Million Adolescents and Adults BlueCross BlueShield MI and Cambia Health Solutions Expand TMS Access for Depressed Adolescents NeuroStar® Launches Better Me Provider Program Nationwide NeuroStar Showcases Cutting-Edge Research at Clinical TMS Society Annual Meeting Neuronetics to Present at the William Blair 44th Annual Growth Stock Conference Humana Is First Commercial Payer to Address TMS Therapy Coverage for Adolescents Neuronetics Reports Record First Quarter 2024 Financial and Operating Results Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Neuronetics to Report First Quarter 2024 Financial and Operating Results and Host Conference Call New Publication in Brain Stimulation Confirms Full TMS Treatment Course Is Vital Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) NeuroStar® Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with Depression Neuronetics Announces 5-Year Exclusive Partnership with Transformations Care Network Neuronetics Reports Record Fourth Quarter and Record Full Year 2023 Financial and Operating Results Neuronetics to Report Fourth Quarter 2023 Financial and Operating Results and Host Conference Call Neuronetics Launches Latest Evolution in its TrakStar® Patient Data Management System NeuroStar TMS Patient Access Expands Through Lucet Health Policy Update Neuronetics Reports Preliminary Fourth Quarter and Fiscal Year 2023 Financial Results Neuronetics Receives 510(k) Clearance for NeuroSite™ Coil Placement Accessory NeuroStar TMS Receives Expanded Regulatory Approval in Japan Neuronetics to Present at the 35th Annual Piper Sandler Healthcare Conference NeuroStar Elevates Depression Treatment with Cutting-Edge Technology Advancements Neuronetics Announces Continued Momentum from Health Plans for TMS Therapy Coverage Neuronetics Reports Third Quarter 2023 Financial and Operating Results Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Neuronetics to Report Third Quarter 2023 Financial and Operating Results and Host Conference Call Neuronetics Draws Down Remaining $22.5 Million Available Under Credit Facility In Recognition of Suicide Prevention Month, NeuroStar Voices Portal Amplifies Stories of Real People Beating Depression NeuroStar Advanced Therapy Wins 2023 dotCOMM Awards Neuronetics Revolutionizes Patient Communication and Provider Support Through Its Exclusive TrakStar® Platform Neuronetics Reports Record Second Quarter 2023 Financial and Operating Results Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Neuronetics to Report Second Quarter 2023 Financial and Operating Results and Host Conference Call Neuronetics Announces Expanded TMS Therapy Access Through Aetna® Health Plans NeuroStar Achieves Milestone Regulatory Clearance in South Korea Neuronetics Receives 510(k) Clearance for OCD MT Cap for NeuroStar Advanced Therapy Neuronetics Announces Increased TMS Access Through BlueCross BlueShield Of Michigan Neuronetics to Present at the William Blair 43rd Annual Growth Stock Conference New Depression Barometer Survey Shows Patients Are Stopping Treatment Due to Dissatisfaction Neuronetics to Present at the JMP Securities Life Sciences Conference Neuronetics Reports Record First Quarter 2023 Financial and Operating Results Neuronetics Receives MDSAP Certification and CE Mark Certification under New MDR Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Neuronetics Showcases New NeuroStar® TMS Findings at Clinical TMS Society Annual Meeting Neuronetics Announces Lisa Metzner-Rosas as SVP, Chief Marketing Officer Neuronetics Announces Expanded TMS Access through United HealthCare Neuronetics to Report First Quarter 2023 Financial and Operating Results and Host Conference Call Neuronetics Announces Continued Momentum for Expanded Health Insurance Coverage for TMS Therapy NeuroStar® Advanced Therapy Enhanced With Wi-Fi Capabilities Neuronetics Secures Up To $60 Million in New Debt Financing with SLR Capital Partners, Provides Greenbrook TMS with $6.0 Million Promissory Note NeuroStar® Advanced Therapy Receives Patient Impact Award from Life Sciences PA Neuronetics Reports Record Fourth Quarter and Record Full Year 2022 Financial and Operating Results Neuronetics Announces TMS Coverage Criteria Changes for Over 23 Million Covered Lives Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Neuronetics Expands NeuroStar® Advanced Therapy’s Proprietary TrakStar® Platform Neuronetics to Report Fourth Quarter 2022 Financial and Operating Results and Host Conference Call Neuronetics Sponsors the 5th International Brain Stimulation Conference Neuronetics Announces Elevation of Sara Grubbs to SVP, Chief Revenue Officer Neuronetics Announces Updated Medicare Policy Expanding Access to NeuroStar TMS Therapy through Nurse Practitioners Neuronetics and Greenbrook TMS Announce Six Year Exclusive Partnership Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Neuronetics Settles Litigation Against BrainsWay Neuronetics Reports Preliminary Fourth Quarter and Fiscal Year 2022 Financial Results Neuronetics Announces Appointment of Joseph H. Capper to its Board of Directors Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Neuronetics Announced as a Winner by 2022 Merit Awards for HealthCare in the Patient Care Category Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Neuronetics Reports Third Quarter 2022 Financial and Operating Results Neuronetics Announced as Winner by 2022 Merit Awards for Technology Neuronetics to Report Third Quarter 2022 Financial and Operating Results and Host Conference Call Neuronetics Launches Innovations To NeuroStar® Advanced Therapy’s Proprietary TrakStar® Platform Neuronetics, Inc. Announces Grand Opening of NeuroStar® University with Ribbon-Cutting Ceremony Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Neuronetics Reports Second Quarter 2022 Financial and Operating Results Neuronetics to Present at the Canaccord Genuity 42nd Annual Growth Conference Neuronetics and Alleviant Health Centers Announce Exclusive Partnership Neuronetics to Report Second Quarter 2022 Financial and Operating Results and Host Conference Call Neuronetics Recognized as Top Non-Invasive Devices Provider in 2022 Neuronetics to Present at the William Blair 42nd Annual Growth Stock Conference New Peer-Reviewed Data Continue to Further Best Practices with NeuroStar® Advanced Therapy Neuronetics Reports First Quarter 2022 Financial and Operating Results Neuronetics and Transformations Care Network Announce Extended Commercial Partnership Neuronetics TMS Leadership on Display at Clinical TMS Society Annual Meeting Neuronetics Files Federal Lawsuit Against Brainsway for Misleading Psychiatrists and Patients Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Neuronetics to Report First Quarter 2022 Financial and Operating Results and Host Conference Call Greenbrook and Neuronetics Announce Strengthened Commercial Partnership to Build Awareness Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Neuronetics Reports Fourth Quarter and Full Year 2021 Financial and Operating Results NeuroStar® Advanced Therapy Launches New “Tap Into a New Possibility” Campaign for Depression Awareness Neuronetics to Report Fourth Quarter and Fiscal Year 2021 Financial and Operating Results and Host Conference Call Neuronetics Announces Amendment of Credit Facility with SLR Investment Corp. Neuronetics Reports Preliminary Fourth Quarter and Fiscal Year 2021 Financial Results Neuronetics Announces Key Role for NeuroStar Advanced Therapy at 4th International Brain Stimulation Conference Neuronetics to Participate at the Piper Sandler 33rd Annual Virtual Healthcare Conference Neuronetics Reports Third Quarter 2021 Financial and Operating Results Neuronetics and River Region Psychiatry Announce Exclusive Partnership Neuronetics Celebrates 235,000 Treatment Milestone for Success TMS Neuronetics to Report Third Quarter 2021 Financial and Operating Results and Host Conference Call CORRECTION - Neuronetics Announces Preliminary Revenue for Third Quarter 2021 Neuronetics Announces Preliminary Revenue for Third Quarter 2021 Neuronetics Announces Commercial Agreement with Success TMS NeuroStar® Advanced Therapy Recognizes National Depression Education and Awareness Month With New Campaign Launch Neuronetics and Zion Healing Announce First Franchise Model for TMS Clinics Neuronetics Launches New Website to Meet Patient Demand for Depression Resources Neuronetics Announces Appointment of Megan Rosengarten to its Board of Directors Neuronetics Reports Second Quarter 2021 Financial and Operating Results Neuronetics to Present at the Canaccord Genuity 41st Annual Growth Conference Neuronetics to Report Second Quarter 2021 Financial and Operating Results and Host Conference Call Neuronetics Launches Enhanced Digital Resource Center for NeuroStar Providers Neuronetics Set to Join Russell 2000® Index Neuronetics Unveils New Clinical Data at Clinical TMS Society 2021 Annual Meeting Neuronetics to Present at The JMP Securities Life Sciences Conference Neuronetics Names Todd Cushman as Vice President, Business Development Neuronetics to Present at the William Blair 41st Annual Growth Stock Conference Neuronetics® Celebrates 100,000 Treatment Milestone for Southern California TMS Center Neuronetics Reports First Quarter 2021 Financial and Operating Results Neuronetics To Present Clinical Data at The American Psychiatric Association 2021 Annual Meeting Neuronetics to Report First Quarter 2021 Financial and Operating Results and Host Conference Call Neuronetics Announces Retirement of Brian Farley and Appointment of Robert Cascella as Chairman of its Board of Directors Neuronetics Announces Appointment of Robert Cascella to its Board of Directors Neuronetics® Celebrates 500,000 Treatment Milestone for Greenbrook® TMS Neuronetics Announces Retirement of Gregory Harper, Vice President, R&D and Clinical Neuronetics Enhances TrakStar® Cloud Patient Data Management System to Maximize Physician Efficiencies Neuronetics Names Cory Anderson Vice President, Clinical Affairs and Medical Operations Neuronetics Reports Fourth Quarter and Full Year 2020 Financial and Operating Results NeuroStar® Advanced Therapy Outcomes Registry Clinical Data Published in Brain Stimulation Validates Depression Treatment Protocols Neuronetics to Report Fourth Quarter and Fiscal Year 2020 Financial and Operating Results and Host Conference Call Neuronetics Announces Strategic Leadership Promotions to Support Future Growth Neuronetics to Participate at the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference Neuronetics Announces Pricing of $75 Million Public Offering of Common Stock Neuronetics Announces Proposed Public Offering of Common Stock NeuroStar® Advanced Therapy’s Depression Outcomes Registry Hits 10,000 Patient Milestone Neuronetics Reports Preliminary Fourth Quarter and Fiscal Year 2020 Financial Results Neuronetics to Participate at the 23rd Annual ICR Westwicke Conference Neuronetics Announces Expansion of Sales Organization Neuronetics Announces the Amendment of Credit Facility with Solar Capital Partners Neuronetics to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference Neuronetics® Receives FDA Clearance for Three-Minute TouchStar™ Treatment Protocol Neuronetics to Present at the Canaccord Genuity Virtual MedTech & Diagnostics Forum Neuronetics Reports Third Quarter 2020 Financial and Operating Results Neuronetics to Report Third Quarter 2020 Financial and Operating Results and Host Conference Call Journal of Affective Disorders Publishes Clinical Data Suggesting NeuroStar® Advanced Therapy as a First-line Treatment for Major Depressive Disorder Neuronetics Appoints Sara Grubbs as Vice President, Sales NeuroStar® Advanced Therapy Providers Offer Free TMS Consultations During National Depression Awareness Month Neuronetics® Celebrates 500,000 Treatment Milestone for Greenbrook® TMS Neuronetics Unveils New Depression Data at Clinical TMS Society’s Virtual Events Neuronetics Reports First Quarter 2020 Financial and Operating Results Neuronetics Reports Second Quarter 2020 Financial and Operating Results Neuronetics Announces the Appointment of Keith J. Sullivan as President and Chief Executive Officer Neuronetics Announces Appointment of Bruce J. Shook to its Board of Directors Neuronetics, Inc. Announces Virtual 2020 Annual Meeting of Stockholders Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Neuronetics Announces the Appointment of Keith J. Sullivan as President and Chief Executive Officer Neuronetics to Present at the William Blair 40th Annual Growth Stock Conference